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Background: Brachial-ankle pulse wave velocity (baPWV), which reflects the stiffness of both central and peripheral
muscular arteries, has been frequently used as a simple index for assessing arterial stiffness. The aim of the present
study was to investigate the prevalence of arterial stiffness in North China based on baPWV measurements, and
explore the associations between increased arterial stiffness and risk factors of cardiovascular diseases (CVD).
Methods: Twenty-three community populations were established in North China. For each participant, parameters
for calculating baPWV, including blood pressures and pressure waveforms, were measured using a non-invasive
automatic device. All participants were required to respond to an interviewer-led questionnaire including medical
histories and demographic data, and to receive blood tests on biochemical indictors.
Results: A total of 2,852 participants were finally investigated. Among them, 1,201 people with low burden of CVD
risk factors were chosen to be the healthy reference sample. The cut-off point of high baPWV was defined as
age-specific 90th percentile of the reference sample. Thus, the prevalence of high baPWV was found to be 22.3%
and 26.4% in men and women respectively. After adjusted for age, heart rate (HR), systolic blood pressure (SBP),
fasting glucose level, and smoking were significantly associated with high baPWV in men; while level of serum total
cholesterol (TC), HR, SBP, and diabetes were significantly associated with high baPWV in women.
Conclusions: Based on the age-specific cut-off points, the middle-aged population has a higher prevalence of high
baPWV in North China. There exists a difference between men and women in terms of the potential risk factors
associated with arterial stiffness.
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Increased arterial stiffness and atherosclerosis are asso-
ciated with several risk factors of cardiovascular diseases
(CVD), such as elevated level of blood glucose, hyper-
tension, obesity, and smoking [1-3]. Pulse wave velocity
(PWV), which reflects the stiffness of both central and
peripheral muscular arteries, can be calculated via non-
invasive measurements. In two previous studies, PWV
was used as a simple index for assessing arterial stiffness
and atherosclerosis [4,5]. And researches [6,7] have* Correspondence: wang-jin-wen@163.com
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reproduction in any medium, provided the ordemonstrated good validity and reproducibility of
brachial-ankle PWV (baPWV), as well as its strong asso-
ciation with central PWV. During the recent years,
baPWV measurements have been carried out in several
university hospitals in China due to its convenience and
importance. Up to now, however, no epidemiological
data on the prevalence of increased arterial stiffness
defined by high baPWV in Chinese population have been
published. Therefore we designed the present study in
order to investigate the prevalence of increased arterial
stiffness in North China based on baPWV measurements.
In addition, preliminary studies based on white
cohorts have shown that PWV is significantly associated
with conventional CVD risk factors, including age,
hypertension, hyperglycemia, and hypercholesterolemiatd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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factors like heart rate (HR) and higher arterial stiffness
remains unclear. Furthermore, no study on the associa-
tions between arterial stiffness and CVD risk factors
based on China’s population has been reported. Conse-
quently, the second aim of this study is to explore the
potential CVD factors associated with arterial stiffness
defined by high baPWV in Chinese community-based
populations.Methods
Participants
The cross-sectional survey was conducted between January
and August 2008. Twenty-three community-based popu-
lations from Beijing and Hebei Province were chosen by
simple random sampling, such that these populations
represented the average standards of living, education,
and health care in North China. Those (n = 5,770) who
were community-dwelling residents aged 18 years or
older in these 23 areas, were located on the basis of
the local resident registry of each community. Being
clearly informed of the study protocol, 3,093/5,770
(53.6%) agreed to participate in this survey. The most
common reason for non-participation (46.7%) was due
to refusal of blood test or examination. Written
informed consent was obtained for each participant,
who was required to correspond to an interviewer-led
questionnaire with questions on smoking habits, occu-
pation, reproductive history, and medical histories.
Trained physicians performed as interviewers. Except
for oral reports, detailed information regarding medical
histories of all participants was provided by community
health service of each community. Approval of this
study was granted by the Institutional Review Board,
Capital Medical University.
Those (241 of 3,093) who had one or more of the fol-
lowing factors were excluded from this study: a) aortic
valve diseases and/or aortic aneurysm, for they are fre-
quently associated with abnormalities of the systemic ar-
terial system, and, in particular, with reduced arterial
compliance, which may have important influence on
PWV; b) history of percutaneous coronary intervention
and/or coronary artery bypass grafting, for these patients
may suffer from potential injuries of arteries due to
puncture or artery harvesting, which might affect the
test result of the automatic device used in the present
study; c) ABI of 0.9 or less, for this indicates the prob-
ability of obstructive arteriosclerosis, which could lead to
a decreased PWV value; and d) ejection fraction < 30%,
for patients with severe heart failure tend to have an
increased PWV.
Finally 2,852 eligible participants were involved. From
these people, a healthy reference sample (n =1,201) wasestablished, for participants of this sample had none of
following issues:
1) hypertension (defined as systolic blood pressure
[SBP] ≥ 140 mmHg and/or diastolic blood pressure
[DBP] ≥ 90 mmHg, and/or antihypertensive drug(s)
usage);
2) diabetes (defined as level of fasting blood glucose ≥
126 mg/dL or receiving insulin therapy and/or taking
anti-diabetic medications);
3) dyslipidemia (defined as serum total cholesterol [TC]
level > 6.2 mmol/L and/or triglycerides [TG] >
2.3 mmol/L or taking lipid-lowering medicines);
4) CVDs (including coronary heart disease, heart
failure, stroke, transient ischemic attack, and/or
intermittent claudication);
5) current smoking (defined as smoking within the past
twelve months);
6) obesity (defined as body mass index [BMI] ≥
30 kg/m2).Measurement of baPWV
An automatic device (ModelBP-203PRE, Colin Inc.,
Komaki, Japan) was used to perform baPWV measure-
ments. Each participant was asked to take five minutes
of rest and then to take examinations in the supine
position with cuffs wrapped both on brachia and on
ankles, electrocardiogram electrodes placed on both
wrists, and a microphone for detecting heart sounds
placed on the left edge of the sternum. The pulse vol-
ume waveforms were recorded via a plethysmographic
sensor connected to the cuffs. Volume waveforms for
the brachium and ankle were stored, then an auto-
matic gain analysis with quality adjustment would be
done after ten seconds’ sampling. Time interval be-
tween the brachial and ankle (Tba) was defined as
time between the initial rise in the brachial and tibial
pressure waveforms. The distance between two sam-
pling points of baPWV could be calculated automatic-
ally based on the subject’s body stature. Both length
and height were measured to the nearest of 1 centi-
meter (cm).The length from aortic valve to ankle (La)
was calculated via the following equation: La (cm) =
0.8129 × height (cm) + 12.328; while that from the aor-
tic valve to the brachia (Lb) was computed using an-
other equation: Lb (cm) = 0.2195 × height (cm) – 2.074.
Finally, based on the equation: baPWV = (La–Lb) /
Tba, value of baPWV was obtained. In the meantime,
bilateral baPWV, brachial and ankle blood pressures,
electrocardiogram, and heart sounds were also obtained
via automatically computation by this device. In this
study, the mean value of the bilateral baPWV, and left
brachial blood pressure were used.
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After 12–15 hours of fasting, a venous blood sample of
10 ml was taken from each subject. The blood samples
were preserved in tubes containing 0.1% EDTA. Plasma
was isolated by centrifugation at 2500 rpm, 4°C, for
20 minutes and then shipped in the frozen state using
dry ice to the central laboratory. Specimens were all
stored at −70°C before laboratory assays was carried
out. Measurements of high density lipoprotein choles-
terol (HDL-C) level complied with that described in
Manual of Laboratory Operations of the Lipid Research
Clinics Program [9], where the intra-assay coefficient of
variation (CV) and inter-assay CV are required to be
1.4% and 2.0% respectively. Levels of TC and TG were
measured using standard enzymatic methods [10], where
intra-assay CV and inter--assay CV are 0.9% and 1.8% re-
spectively for TC, 1.5% and 1.9% respectively for TG.
Levels of fasting glucose were measured using the hexo-
kinase method, where intra-assay and inter-assay CV are
required to be 1.9% and 2.6% respectively. For those with
TG < 400 mg/dl, low-density lipoprotein cholesterol
(LDL-C) levels were calculated using the Friedewald
equation [11]: LDL C TCHDLCTCS . No participant
with TG ≥ 400 mg/dl was found in this investigation. The
central laboratory of The Military General Hospital of
Beijing PLA was responsible for all the blood tests in this
study. The internal and external quality controls proce-
dures were performed in accordance with regulations of
Chinese Laboratory Quality Control.Statistical analysis
Statistical analyses were performed using the SPSS for
Windows statistical software package version 15.0 (SPSS
Inc., Chicago, IL, USA). Continuous variables were
expressed as mean ± standard deviation (SD) unless
otherwise indicated. Differences in continuous variables
between the subjects with and without high baPWV
were tested with Student’s t test, including age, BMI,
SBP, DBP, HR, and levels of TC, HDL-C, LDL-C, TG
and fasting glucose. Differences in binomial categorized
variables between the two groups were analyzed with
Person’s Chi-square test, including hypertension (yes/
no), diabetes (yes/no), smoking (yes/no, defined as
smoking regularly over the prior 12 months), ischemic
heart disease (yes/no), stroke (yes/no), angiotensin con-
verting enzyme inhibitors (ACEIs) and/or angiotensin
receptor blockers (ARBs) usage (yes/no), statins usage
(yes/no), calcium-channel blockers (CCBs) usage (yes/
no). Considering the difference between men and wo-
men, we performed multiple analyses in two genders
separately. Age-specific cut-off points for high baPWV
were defined as the 90th percentiles in each age group
of the healthy reference sample respectively.Multivariate analyses based on multiple backward
stepwise logistic regression were also performed to test
the associations between potential risk factors and
increased arterial stiffness defined as high baPWV, in
men and women separately. Variables were considered
for entry into the multiple logistic models were age,
BMI, HR, SBP, DBP, HR, TC, HDL-C, TG, fasting glu-
cose, diabetes, ischemic heart disease, hypertension,
stroke, smoking, statin usage, ACEIs and/or ARBs usage,
and CCBs usage. The standard used for a variable enter-
ing or not entering the multivariate analysis was based
on p < 0.10 yielded by univariate analysis, and/or its
potential clinical significance on the basis of previous
studies and clinical practice. The criterion for inclusion
of variables was p < 0.05, and that for exclusion was
p > 0.10. All p values reported are two-tailed and p < 0.05
was considered to be statistically significant.
Results
A total of 2,852 subjects were finally investigated. The
demographic data, disease characteristics, and mean
values of biochemical indictors of the study population
are shown in Table 1.
Table 2 shows the age-specific mean values and 90th
percentile upper limits for baPWV, defined as cut-off
points, in both genders of the healthy reference sample.
The cut-off points of baPWV increased substantially
with the advancing age in the healthy sample.
The sex-specific prevalence of high baPWV was calcu-
lated based on cut-off points listed in table 2, and is
shown in Table 3. In the study population as a whole,
the prevalence of high baPWV was 24.5% (22.30% in
men and 26.40% in women). In men, the 50–59 years
age group had the highest prevalence of high baPWV
(39.6%), while the 60–69 years age group had the highest
prevalence of high baPWV (38.8%) in women.
The study population was divided into two groups
based on the cut-off points of each age group, in men
and in women respectively. As shown in Tables 4 and 5,
compared with participants with low baPWV, those with
high baPWV were significantly older (in men: 52.3 ±
16.2 vs. 53.2 ± 13.6, p < 0.001; in women: 52.8 ± 15.2 vs.
58.1 ± 13.2, p < 0.001), and had a higher HR (70 ± 10 vs.
74 ±11, p < 0.001 in men; and 71 ± 9 vs. 75 ± 11, p < 0.001
in women) and level of fasting glucose (5.3 ± 1.2 vs. 5.9 ±
1.9, p < 0.001 in men; and 5.31 ± 1.5 vs. 5.89 ± 1.9, p < 0.001
in women) than those with low baPWV. Though women
with high baPWV had a significantly greater BMI (23.9 ±
3.3 vs. 24.4 ± 3.7, p = 0.026), it was not the case for men
(24.5 ± 3.3 vs. 25.5 ± 2.9, p = 0.069). Also, ACEIs/ARBs
and CCB usage were both more prevalent in high
baPWV group than in low baPWV group, irrespective of
sex group. Prevalence of diabetes and hypertension were
both higher in those with high baPWV compared with
Table 1 Characteristics of study population
Healthy sample Overall sample
male female male female
N 342 859 1275 1577
Age , years 46.2 ± 15.4 46.7 ± 13.8 52.5 ± 12.7 54.0 ± 14.9
BaPWV, cm/s 1339.3 ± 224.8 1294.8 ± 241.9 1524.8 ± 355.7 1578.6 ± 463.6
BMI, kg/m2 23.8 ± 2.9 22.8 ± 2.9 24.7 ± 3.2 23.9 ± 3.4
MAP, mmHg 89.8 ± 7.3 85.3 ± 8.8 97.9 ± 18.8 94.7 ± 13.3
SBP, mmHg 123.9 ± 13.2 120.6 ± 12.1 131.8 ± 17.9 130.9 ± 20.9
DBP, mmHg 74.4 ± 7.5 70.2 ± 8.4 80.9 ± 24.1 76.6 ± 10.9
Pulse pressure, mmHg 46.0 ± 7.9 45.3 ± 9.1 50.9 ± 24.9 54.5 ± 14.9
HR, beats/min 70.8 ± 9.4 71.4 ± 9.4 70.9 ± 10.2 71.6 ± 10.1
TC, mmol/L 4.57 ± 0.81 4.75 ± 0.94 4.73 ± 0.94 5.09 ± 1.06
HDL-C, mmol/L 1.37 ± 0.29 1.44 ± 0.33 1.29 ± 0.29 1.39 ± 0.33
LDL-C, mmol/L 2.67 ± 0.62 2.75 ± 0.83 2.81 ± 0.76 3.02 ± 0.91
TG, mmol/L 1.53 ± 1.04 1.31 ± 0.87 1.80 ± 1.27 1.59 ± 0.99
Fasting glucose, mmol/L 4.9 ± 0.6 4.9 ± 0.5 5.4 ± 1.4 5.4 ± 1.6
Hypertension, % 0 0 50.3 47.8
Diabetes, % 0 0 23.7 21.1
Smoking, % 0 0 50.2 3.7
Stroke, % 0 0 7.2% 6.5%
Ischemic heart disease, % 0 0 10.9 7.1
Medication
ACEIs/ARBs, % 0 0 9.9 8.9
Statins, % 0 0 6.6 4.9
CCBs, % 0 0 15.3 14.5
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, MAP Mean arterial pressure; BaPWV Brachial-ankle pulse wave velocity, CCBs
Calcium channel blockers, ACEIs angiotensin converting enzyme inhibitors, ARBs angiotensin receptor blockers, HR heart rate, TC total cholesterol, LDL-C low
density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, TG triglyceride.
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blood lipid indices (TC, TG, HDL-C, LDL-C) tested, no
significant difference was found between the two groups
in men, while they were higher in high baPWV group in
women. Smoking was significantly more prevalent in the
high baPWV group than the other in men rather than in
women.Table 2 Age-specific cut-off points of BaPWV* in male
and female in the healthy reference sample
Age(n) Mean 90th percentile (cut-off)
male female male female
<29 (229) 1200 1125 1340 1285
30-39 (375) 1253 1184 1454 1354
40-49 (475) 1309 1241 1520 1412
50-59 (733) 1330 1353 1503 1603
60-69 (556) 1571 1572 1914 1858
>70 (484) 1759 1805 2441 2368
* BaPWV Brachial-ankle pulse wave velocity.Results of multiple backward stepwise logistic regres-
sion analyses in male and female population are shown
in Table 6. Based on the entry criteria mentioned in the
statistical analysis section, variables entering the multiple
logistic regression analysis included age (per 1 year), SBP
(per 1 mmHg), DBP (per 1 mmHg), HR (per 1 beat/
min), fasting glucose (per 1 mmol/L), diabetes (yes/no),
hypertension (yes/no), CCBs usage (yes/no), ACEIs/Table 3 Prevalence of high baPWV* by age group
Age (n) Male Female
<29 (229) 23.6% 10.6%
30-39 (375) 16.1% 14.2%
40-49 (475) 18.8% 25.9%
50-59 (733) 39.6% 26.6%
60-69 (556) 17.6% 38.8%
>70 (484) 11.2% 26.1%
Overall 22.3% 26.4%
* BaPWV Brachial-ankle pulse wave velocity.
Table 4 Characteristics of male participants with vs.








Age , years 52.3 ± 16.2 53.2 ± 13.6 <0.001
baPWV, cm/s 1432 ± 269 1854 ± 424 <0.001
BMI, kg/m2 24.5 ± 3.3 25.5 ± 2.9 0.069
SBP, mmHg 128.2 ± 15.7 144.4 ± 19.4 <0.001
DBP, mmHg 79.0 ± 26.3 87.6 ± 11.5 <0.001
HR, beats/min 70 ± 10 74 ±11 <0.001
TC, mmol/L 4.7 ± 0.9 4.8 ± 0.9 0.995
HDL-C, mmol/L 1.3 ± 0.3 1.3 ± 0.3 0.870
LDL-C, mmol/L 2.8 ± 0.8 2.9 ± 0.7 0.407
TG, mmol/L 1.8 ± 1.3 1.9 ± 1.3 0.751
Fasting glucose,
mmol/L
5.3 ± 1.2 5.9 ± 1.9 <0.001
Hypertension, % 42.4 78.3 <0.001
Diabetes, % 20.7 34.5 <0.001
Smoking, % 47.8 58.1 0.003








Statins usage, % 6.8 5.7 0.586
CCBs usage, % 12.8 24.2 <0.001
* The cut-off refers to the corresponding cut-off point to each age group.
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood
pressure, MAP Mean arterial pressure; BaPWV Brachial-ankle pulse wave
velocity, CCBs Calcium channel blockers, ACEIs angiotensin converting enzyme
inhibitors, ARBs angiotensin receptor blockers, HR heart rate, TC total
cholesterol, LDL-C low density lipoprotein cholesterol, HDL-C high density
lipoprotein cholesterol, TG triglyceride.
Table 5 Characteristics of female participants with vs.








Age , years 52.8 ±15.2 58.1 ± 13.2 <0.001
baPWV, cm/s 1441 ± 318 2038 ± 566 <0.001
BMI, kg/m2 23.9 ± 3.3 24.4 ± 3.7 0.026
SBP, mmHg 126.9 ± 19.5 144.2 ± 20.0 <0.001
DBP, mmHg 74.8 ± 10.5 82.5 ± 10.4 0.615
HR, beats/min 71 ± 9 75 ±11 <0.001
TC, mmol/L 4.99 ± 1.0 5.38 ±1.1 <0.001
HDL-C, mmol/L 1.41 ± 0.3 1.35 ±0.3 0.003
LDL-C, mmol/L 2.95 ± 0.9 3.19 ±0.9 <0.001
TG, mmol/L 1.51 ± 0.9 1.80 ± 1.1 <0.001
Fasting glucose,
mmol/L
5.31 ± 1.5 5.89 ± 1.9 <0.001
Hypertension, % 40.1 73.3 <0.001
Diabetes, % 17.9 31.9 <0.001
Smoking, % 3.6 4.1 0.638








Statins usage, % 4.6 6.1 0.271
CCBs usage, % 11.2 25.3 <0.001
* The cut-off refers to the corresponding cut-off point to each age group.
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood
pressure, MAP Mean arterial pressure; BaPWV Brachial-ankle pulse wave
velocity, CCBs Calcium channel blockers, ACEIs angiotensin converting enzyme
inhibitors, ARBs angiotensin receptor blockers, HR heart rate, TC total
cholesterol, LDL-C low density lipoprotein cholesterol, HDL-C high density
lipoprotein cholesterol, TG triglyceride.
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while in women, the included variables were age (per 1
year), SBP (per 1 mmHg), BMI (per 1 kg/m2), HR (per 1
beats/min), TC (per 1 mmol/L), HDL-C (per 1 mmol/L),
TG (per 1 mmol/L), fasting glucose (per 1 mmol/L), dia-
betes (yes/no), hypertension (yes/no), CCBs usage (yes/
no), ACEIs/ARBs usage (yes/no). As shown in Table 6,
variables positively associated with high baPWV were
HR (OR = 1.029, [1.015, 1.044], p < 0.001), SBP (OR =
1.055, [1.045, 1.065], p < 0.001), fasting glucose level
(OR = 1.023, [1.086 to 1.331], p < 0.001) and smoking
(OR = 1.271, [0.944, 1.710], p = 0.032) in men; while in
women, the variables were SBP (OR = 1.048, [1.040,
1.056], p < 0.001), diabetes (OR = 1.835, [1.299, 2.593],
p = 0.001), TC levels (OR = 1.220, [1.076, 1.384], p = 0.002)
and HR (OR = 1.044, [1.032, 1.056], p < 0.001).Discussion
Early detection of arterial stiffness is useful in primary
and secondary prevention of a series of major CVD like
coronary artery disease and hypertension. Several studies
have shown that PWV was an independent predictor of
future development of CVD [12,13]. The baPWV meas-
urement is noninvasive and convenient, and has been
used for cardiovascular risk stratification [14]. For the
first time, the present study investigated the prevalence
of arterial stiffness in North China on the basis of a 23-
community-based study population, and explored the as-
sociation between high baPWV and CVD risk factors
based on general population other than highly character-
istic cohorts. Also, the age-specific cut-off points of
baPWV were determined and evaluated in terms of its
associations with increased arterial stiffness defined by
Table 6 Associations between high baPWV* and potential risk factors based on the multiple logistic regression
analyses†
Variables‡ Male Female
OR (95% CI) p value OR (95% CI) p value
SBP, per 1 mmHg 1.055 (1.045, 1.065) < 0.001 1.048 (1.040, 1.056) < 0.001
HR, per 1 beats/min 1.029 (1.015, 1.044) < 0.001 1.044 (1.032, 1.056) < 0.001
TC, per 1 mmol/L ─ a ─ 1.220 (1.076, 1.384) 0.002
Fasting glucose, per 1 mmol/L 1.203 (1.086, 1.331) < 0.001 ─ ─
Hypertension (yes/no) ─ ─ ─ ─
Diabetes (yes/no) ─ ─ 1.835 (1.299, 2.593) 0.001
Smoking (yes/no) 1.271 (0.944, 1.710) 0.032 ─ ─
* High baPWV was defined based on age-specific cut-off points.
† The backward stepwise method was used.
‡ Only those that entered the final step of backward stepwise logistic regression were shown in the table. Originally, variables entering the multiple logistic
regression model included age, SBP, DBP, HR, fasting glucose, diabetes, hypertension, CCBs usage, ACEIs/ARBs usage, and smoking in men; while in women, the
included variables were age, SBP, BMI, HR, TC, HDL-C, TG, fasting glucose, diabetes, hypertension, CCBs usage, ACEIs/ARBs usage.
a The symbol “─“ represents covariates that did not significantly contribute to the model or were not included.
OR odds ratio, CI confidence interval, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, CCBs Calcium channel blockers, ACEIs
angiotensin converting enzyme inhibitors, ARBs angiotensin receptor blockers, HR heart rate, TC total cholesterol, HDL-C high density lipoprotein cholesterol,
TG triglyceride.
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population.
The present data indicated that males had a higher
average and upper limit baPWV values than females. In
the healthy reference aged 50–59 years, women had a
higher age-specific cut-off value of arterial stiffness than
men did. Previous researches have indicated that estro-
gen have beneficial effects on arterial stiffness. A Japanese
study reported that the menopause augments the age-
related increase in arterial stiffness during the early post-
menopausal phase and that this augmentation is probably
related, at least in part, to estrogen deficiency [15]. Also,
Sztejnsznajd and et al. claimed that long-term administra-
tion of oral estrogens leads to an improvement in arterial
distensibility in postmenopausal women [16]. The mean
age of natural menopause in China was 48.7 years accord-
ing to a recent study [17]. Therefore, we may infer that de-
crease of estrogen in menopause might take effect on the
arterial stiffness.
The male participants in 50–59 years age group had
the greatest prevalence of arterial stiffness, while it was
the case in 60–69 years age group of female participants.
Considering that arterial stiffness had been associated
with the risk of CVD, the present result may suggest that
the burden of CVD associated to arterial stiffness rise to
the greatest extent in middle-age population. It should
be pointed out that, were the cut-off points for high
PWV defined irrespectively of age group, the prevalence
of “high baPWV” would have gone up sharply with in-
creasing age in both genders. However, results in this
circumstance would be invalid due to the confounding
effects of age. Two recent studies showed that higher
baPWV was associated with an increased risk total mor-
tality [18,19], and inferred that healthiest people withlower baPWV are more likely to survive past 60 years.
This might contribute to a greater prevalence of high
baPWV in middle-aged group. Follow-up of the present
study is expected to further the interpretation.
In this study, the identified potential risk factors of ar-
terial stiffness based on baPWV measurement were fas-
ter HR, higher SBP, higher fasting glucose level, and
smoking in men, while were HR, SBP, TC level, and dia-
betes in women. Two previous studies observed the
presence of increased arterial stiffness in patients with
hypertension, dyslipidemia and/or diabetes [20,21]. The
present data suggested that SBP should be an important
clinical indicator of increased arterial stiffness both in
men and in women.
Smoking is another major risk factor in the develop-
ment and progression of CVD [22]. This study indicated
that it may also be responsible for greater arterial stiff-
ness, especially in men. Alterations in hemostatic factors
and injury to the vascular endothelial function may play
an important role in increasing arterial stiffness [23].
The reason why no significant association was found be-
tween smoking and baPWV in women is probably due
to the fact that the small number of female smokers
could not yield statistical significance.
The present data showed that the higher HR was sig-
nificantly associated with the high baPWV in men and
in women. HR changes can influence arterial distensibil-
ity [24]. An epidemiological study assessed the relation-
ship between HR and PWV and demonstrated that there
was a statistically significant positive link between the
higher HR and the higher arterial stiffness [25]. It is
worth further investigation that whether lowering HR
therapy using β-blockers or other methods benefits
patients with increased arterial stiffness or not. Obesity
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stiffness [26]. However, we found no significant relation
between BMI and baPWV in multivariable models. This
is partly due to the low prevalence of obesity in the
population, which limits power to detect a relation.
The strength of this study is a multi-community-based
general population with the large sample size, which
makes it possible to stratify subjects by age group, and
results generalizable to individuals in different ages.
However, the present study has limitations. Firstly, re-
sponse rate was 53.6%. A low response rate may give rise
to sampling bias if the nonresponse is unequal among
the participants regarding exposure and/or outcome.
Though the most common reason was refusal of exami-
nations, it was unclear that whether other reasons not to
participate related to factors associated with arterial stiff-
ness. Secondly, the present study did not examine mar-
kers of inflammation and renal function, and therefore,
could not evaluate this particular relationship. Besides,
the limitation of the cross-sectional design was also a
fact in this study. The prognostic significance of the
baPWV could not be evaluated. Finally, the population
was from North China, and may not suitable applied for
south areas of China and other countries. Longitudinal
studies with a large sample size and a follow-up of the
present study are expected to further explore these
questions.
Conclusions
The prevalence of arterial stiffness based on high
baPWV was 22.30% in men and 26.40% in women re-
spectively in the North China. On the basis of the age-
specific cut-off points, the middle-age population had
the highest prevalence of high baPWV. The factors asso-
ciated with arterial stiffness were HR, SBP, fasting glu-
cose level, and smoking in men, while TC, HR, SBP, and
diabetes in women.
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